The first scoring system devised specifically for patients with unclassifiable cases of myelodysplastic syndrome and MDS/myeloproliferative neoplasms has identified several factors helpful in predicting survival outcomes, according to a study presented during the 54th American Society of Hematology Annual Meeting and Exposition.
The presence of comorbidity or symptom burden in long-term survivors of non-Hodgkin lymphoma should alert the clinician to a potential need for supportive services.
Once-daily ponatinib, a pan-BCR-ABL inhibitor, was “highly active” in heavily pretreated patients with Philadelphia chromosome-positive leukemias resistant to tyrosine kinase inhibitors.
Seattle Genetics announced that Adcetris (brentuximab vedotin) has been granted orphan drug designation by the FDA for the treatment of mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL).
Profound immunodeficiency and high HIV-1 viral load in patients with AIDS-related lymphoma “do not preclude attainment of complete response.
Use of high-dose vincristine sulfate liposome injection monotherapy in patients with advanced Philadelphia chromosome-negative acute lymphoblastic leukemia resulted in “meaningful clinical outcomes” that included durable responses and bridging to hematopoietic cell transplantation.
Absence of positive bone marrow biopsy for patients with PET/CT-assessed stage I, II disease.
The antibody conjugate gemtuzumab ozogamicin (GO) reduces relapse rates and might improve 3-year survival rates among older patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome.
Use of the gonadotropin-releasing hormone agonist triptorelin did not significantly decrease risk of chemotherapy-induced premature ovarian failure after 1 year of follow-up in young patients treated for Hodgkin or non-Hodgkin lymphoma.
Bortezomib added to standard 3+7 daunorubicin and cytarabine induction chemotherapy in patients aged 60 to 75 years with previously untreated acute myeloid leukemia (AML) “resulted in an encouraging remission rate,” investigators concluded in the Journal of Clinical Oncology online November 5.
